EQS-News: Formycon AG / Key word (s): Regulatory Approval Formycon receives EU approval for FYB203 (aflibercept), a biosimilar to Eylea®, under the brand names AHZANTIVE® and Baiama® 20.01.2025 / ...

A clever new set of glasses may offer new hope to people with macular degeneration. By copying the structure of a fly's eyes, ...

Another common early symptom is blurry or distorted vision. Straight lines, like those on a doorframe or a tiled floor, may ...

The phase 1 clinical trial is a multicenter, open-label, dose-escalation study to assess drug safety via intravitreal ...

The Amsler grid is a simple and effective tool often used to detect early signs of macular degeneration. This is a grid of ...

University of California San Diego researchers have identified a U-shaped association between high-density lipoprotein (HDL) ...

Age-related macular degeneration (AMD), which affects about 200 million people worldwide and can result in legal blindness, impairs an area of the eye (retina) used for reading, driving and many other ...

In this video, Clement K. Chan, MD, FACS, discusses a presentation from the AAO meeting on multimodal imaging to assess geographic atrophy.In a session on diagnostic techniques for identifying and ...

Age-related macular degeneration (AMD), which affects about 200 million people worldwide and can result in legal blindness, ...

ACDN-01 is under clinical development by Ascidian Therapeutics and currently in Phase II for Juvenile Macular Degeneration (Stargardt Disease). According to GlobalData, Phase II drugs for Juvenile ...

KSI-501 is under clinical development by Kodiak Sciences and currently in Phase III for Wet (Neovascular / Exudative) Macular Degeneration. According to GlobalData, Phase III drugs for Wet ...